

Date: February 06, 2024

To,
Listing Compliance Department
BSE Limited
PJ Towers, Dalal Street,
Mumbai 400001, MH

Stock Code: 542248

Subject: Outcome of the Board Meeting held on today i.e. February 06, 2024 and Submission of Unaudited Financial Results (Standalone & Consolidated) for the quarter ended December 31, 2023

Dear Sir/Madam,

With reference to our Intimation vide letter dated Monday, January 29, 2024 we wish to inform you that the Board Directors of the Company in its meeting held today i.e. Tuesday, February 06, 2024 through Video Conferencing/OAVM have Inter-alia;

1. Considered and Approved the Standalone Unaudited Financial Results of the Company for the quarter ended December 31, 2023 along with the Limited Review Report.
2. Considered and Approved the Consolidated Unaudited Financial Results of the Company for the quarter ended on December 31, 2023 along with the Limited Review Report.
3. On the recommendation of the Nomination and Remuneration Committee, unanimously approved the appointment Bhavika Sanghani (DIN-10492381) , as an Additional Director of the company in the category of Independent Director for a term of 5 (Five) years with effective from February 06, 2024, subject to approval of shareholders of the Company.
4. On the recommendation of the Nomination and Remuneration Committee, unanimously approved the appointment of Mr. Umanja Venkata Satya Siva Srihari Kolla (DIN: 01638116), as an Additional Director of the company in the category of Non-Executive and Non Independent Director with effective from February 06, 2024 as, liable to retire by rotation and recommended for the approval of the members.

Registered office:

CIN: L72200TG1996PLC024351. Estd: 1996
Address : H.No. 6-3-348/4, Dwarkapuri
Colony, Punjagutta, Hyderabad,
Telangana-500082

Innovation Hub & manufacturing:

Address: Plot No.13, Sector-03, (SIDCUL), IIE,
Panthenagar, Udam Singh Nagar
-263153,U.K., India



5. Approved the appointment of M/s Malay Agarwal (FRN-437347), Chartered Accountants, as Internal Auditor for Internal Audit of the Company w.e.f. F.Y. 2023-24.

Details as required under regulation 30 of listing regulations read with SEBI circular SEBI/HO/CFD/CFDPOD-1/P/CIR/2023/123 dated July 13, 2023 are provided herewith.

The Board Meeting commenced at 03:30 PM and concluded at 3:55 PM


Further the said outcome shall be uploaded on the website of the company at www.deccanhealthcare.co.in.

We request you to take the same on records.

Thanking You,

For and on behalf of

Deccan Health Care Limited




Vaishali Gagnani

Company Secretary

M. no. A58408

Encl: a/a

Registered office:

CIN: L72200TG1996PLC024351. Estd: 1996

Address : H.No. 6-3-348/4, Dwarkapuri
Colony, Punjagutta, Hyderabad,
Telangana-500082

Innovation Hub & manufacturing:

Address: Plot No.13, Sector-03, (SIDCUL), IIE,
Panthnagar, Udam Singh Nagar
-263153,U.K., India

Date: February 06, 2024

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street,
Mumbai – 400001, Maharashtra

Stock Code: 542248

Subject: Submission of standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended on December 31, 2023 along with Limited Review Reports issued by Statutory Auditors

Dear Sir/Madam

With reference to above captioned subject and pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended December 31, 2023 along with the Limited Review Report issued by Statutory Auditors.

The said Financial Results were duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

We request you to take the same on records.

Thanking You,
Yours Faithfully,
For and on behalf of

Deccan Health Care Limited

Vaishali Gagnani



Vaishali Gagnani
Company Secretary
M. no. A58408
Encl: a/a

Registered office:

CIN: L72200TG1996PLC024351. Estd: 1996
Address : H.No. 6-3-348/4, Dwarkapuri
Colony, Punjagutta, Hyderabad,
Telangana-500082

Innovation Hub & manufacturing:

Address: Plot No.13, Sector-03, (SIDCUL), IIE,
Panthnagar, Udam Singh Nagar
-263153,U.K., India



Independent Auditor's Limited Review Report on the Quarter Unaudited Standalone Financial Results of the Deccan Health Care Limited, for the quarter ended 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Deccan Health Care Limited

We have reviewed the accompanying the statement of unaudited Standalone financial results of **Deccan Health Care Limited** for the Quarter ended **December 31, 2023** attached herewith, being submitted by the company pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement, which is the responsibility of the Company Management and approved by the Company Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable Indian Accounting standard ("Ind AS") and other recognized accounting practices and policies as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Associates

Chartered Accountants

F.R.No. 333288W



Akhlaq Ahmad Mutvalli

Partner

Membership Number:-181329

UDIN: -24181329BKCBTJ4984

Date:-06th February, 2024

Place:-Ahmedabad

Deccan Health Care Limited

CIN : L72200TG1996PLC024351

Registered Office:H.No. 6-3-348/4, Dwarkapuri Colony, Punjagutta, Hyderabad, Telangana, India, 500082

Standalone Financial Results For The Quarter & Nine Months Ended 31st December, 2023

Sr. No.	Particulars	Rs. in Lakhs (unless otherwise stated)					
		Quarter Ended			Period Ended		Year Ended
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Income From Operations						
	a) Revenue from Operations	1,534.31	1,719.45	864.61	4,376.07	2,916.24	4,502.16
	b) Other Income	0.03	0.03	0.96	0.66	1.11	1.64
	Total Income	1,534.34	1,719.48	865.57	4,376.73	2,917.35	4,503.80
II	Expenses						
	a) Cost of Materials Consumed	1,142.42	366.94	1,178.76	2,037.35	2,131.26	3,196.46
	b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	30.34	667.34	(602.69)	716.32	(631.25)	(699.56)
	c) Employee Benefit Expense	87.42	54.46	79.70	242.13	250.86	323.92
	d) Finance Costs	1.52	0.34	3.63	3.96	8.45	11.40
	e) Depreciation and Amortisation Expense	39.95	31.64	35.57	110.93	107.19	142.75
	f) Other Expenses	150.59	527.77	227.40	1,071.33	1,039.25	1,475.72
	Total Expenses	1,452.24	1,648.49	922.37	4,182.02	2,905.76	4,450.69
III	Profit/ (Loss) Before Tax (I-II)	82.10	70.99	(56.80)	194.71	11.59	53.11
IV	Tax Expense						
	a) Current Tax	32.16	19.72	(10.30)	66.41	9.13	21.83
	b) Deferred Tax (Asset)/Liabilities	(5.13)	(1.64)	(3.79)	(11.03)	(6.22)	(8.47)
	Total Tax Expense	27.03	18.08	(14.09)	55.38	2.91	13.36
V	Net Profit/ (Loss) After Tax for the Period (III-IV)	55.07	52.91	(42.71)	139.33	8.68	39.75
VI	Other Comprehensive Income/ (Loss)						
	Items that will not be reclassified to profit & loss (net of tax)	(1.58)	(2.49)	(1.44)	(4.73)	(4.31)	(5.74)
	Items that will be reclassified to profit & loss (net of tax)	-	-	-	-	-	-
	Total Other Comprehensive Income/ (Loss)	(1.58)	(2.49)	(1.44)	(4.73)	(4.31)	(5.74)
VII	Total Comprehensive Income/ (Loss) for the period (V+VI)	53.49	50.41	(44.15)	134.60	4.37	34.01
VIII	Paidup Equity Share Capital (Facevalue Rs 10 each)	2,037.62	1,704.32	1,704.32	2,037.62	1,704.32	1,704.32
IX	Earnings Per Share						
	Earnings Per Share (not annualised for quarter/ year / period ended)						
	Basic / Diluted	0.31	0.31	(0.25)	0.77	0.06	0.24
	Basic / Diluted (After Adjustment to Bonus Issue)	0.31	0.31	(0.25)	0.77	0.06	0.24



Notes to Accounts -Standalone Financial Statement

[1] The above standalone financial results for the quarter ended December 31, 2023 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 06-02-2024. A limited review of the above results has been carried out by the statutory auditors of the company.

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as ammended] precribed under section 133 of the companies act,2013.

[4] The Management is in process of identifying parties which are covered under MSME, The Amount relating to MSME are disclosed to the extent identified.

[5] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[6] During the Quarter ended on 31.12.2023 Company has allotted 33,33,000 Equity shares as on 12.10.2023 at face value of Rs. 10.00 each at an issue Price Of Rs. 30.00 Per Equity Share(including Security Premium Of Rs. 20.00 per Equity Share). And the funds has been utilised as per the object.

[7] During the Quarter ended on 31.12.2023 Company has issued 53,73,000 Convertible Warrants as on 12.10.2023 at a face value of Rs. 10.00 each, at an issue Price Of Rs. 30.00 per Warrants(including Security Premium Of Rs 20.00 per Equity Share), aggregating to Rs. 16,11,90,000 /- From Which 25% Amount Received on Issue Of Warrants. And the funds has been utilised as per the object.

[8] The figure for the quarter ended 31.12.2023 are balancing figures between the unaudited figures in respect of half year ended on 30.09.2023 and the nine month ended figures upto the third quarter ended on 31.12.2023 which were subject to limited review.


[9] The figure for the quarter ended 31.12.2022 are balancing figures between the unaudited figures in respect of half year ended on 30.09.2022 and the nine month ended figures upto the third quarter ended on 31.12.2022 which were subject to limited review.

[10] The figure for the Nine Month ended on 31.12.2022 are balancing figures between the audited figures in respect of year ended on 31.03.2023 and the quarter ended figures on 31.03.2023.

[11] The Status of investor's complaints during the period ended on December 31 ,2023 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

For, Deccan Health Care Limited


Minto P. Gupta
(Managing Director)
(DIN: 00843784)



Date:- 06th February, 2024
Place: Hyderabad



Auditor's Limited Review Report on unaudited Consolidated Financial results of Deccan Health Care Limited, for the Quarter ended December 31, 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Deccan Health Care Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Deccan Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2023. ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Deccan Health Care Limited ("Parent")
2. Beyoungstore Private Limited ("Subsidiary")


Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the statement provided by the Management related to subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



We did review the interim financial statements / financial information / financial results of Beyoungstore Private Limited ("subsidiary") included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 7.50 Lakhs ,and total net profit/(loss) before tax of Rs. (3.56) lakhs, for the quarter ended December 31, 2023, as considered in the consolidated unaudited financial results, whose interim financial statements / financial information/ financial results have been reviewed by us. These interim financial statements / financial information / financial results have been provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the Management and the procedures performed by us as stated in above.


Our conclusion on the statement is not modified in respect of the above matters.

For Keyur Shah & Associates
Chartered Accountants
FRN. 333288W



Akhlaq Ahmad Mutvalli
Partner

Membership Number:-181329
UDIN: -24181329BKCBTK6998



Date:-06th February, 2024
Place:-Ahmedabad

Deccan Health Care Limited

CIN : L72200TG1996PLC024351

Registered Office:H.No. 6-3-348/4, Dwarkapuri Colony, Punjagutta, Hyderabad, Telangana, India, 500082

Consolidated Financial Results For The Quarter & Nine Months Ended 31st December, 2023

Rs. in Lakhs (unless otherwise stated)

Particulars	Quarter Ended		Period Ended		Year Ended	
	31/12/2023	30/09/2023	31/12/2022	31/12/2023	31/03/2023	
	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Income From Operations						
a) Revenue from Operations	1,534.31	1,719.45	864.61	4,376.07	2,916.24	4,502.16
b) Other Income	0.03	0.06	0.96	0.72	1.41	1.94
Total Income	1,534.34	1,719.51	865.57	4,376.79	2,917.65	4,504.10
Expenses						
a) Cost of Materials Consumed	1,142.42	366.94	1,178.76	2,037.35	2,131.26	3,196.46
b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	30.34	667.34	(602.69)	716.32	(631.25)	(699.56)
c) Employee Benefit Expense	90.19	57.35	83.29	250.86	255.28	332.26
d) Finance Costs	3.64	0.35	3.64	6.09	8.47	11.43
e) Depreciation and Amortisation Expense	39.95	31.64	35.57	110.93	107.19	142.75
f) Other Expenses	149.22	523.62	225.75	1,064.39	1,038.16	1,476.79
Total Expenses	1,455.76	1,647.24	924.32	4,185.94	2,909.11	4,460.13
Profit/ (Loss) Before Tax (I-II)	78.58	72.27	(58.75)	190.85	8.54	43.97
Tax Expense						
a) Current Tax	31.19	19.88	(8.76)	65.44	10.67	21.83
b) Deferred Tax (Asset)/Liabilities	(5.13)	(1.64)	(3.79)	(11.03)	(6.22)	(8.47)
Total Tax Expense	26.06	18.24	(12.55)	54.41	4.45	13.36
Net Profit/ (Loss) After Tax for the Period (III-IV)	52.52	54.03	(46.20)	136.44	4.09	30.61
Other Comprehensive Income/ (Loss)						
Items that will not be reclassified to profit & loss (net of tax)	(1.57)	(2.50)	(1.44)	(4.73)	(4.31)	(5.74)
Items that will be reclassified to profit & loss (net of tax)	-	-	-	-	-	-
Total Other Comprehensive Income/ (Loss)	(1.57)	(2.50)	(1.44)	(4.73)	(4.31)	(5.74)
Total Comprehensive Income/ (Loss) for the period (V+VI)	50.95	51.53	(47.64)	131.71	(0.22)	24.87
Paidup Equity Share Capital (Facevalue Rs 10 each)	2,037.62	1,704.32	1,704.32	2,037.62	1,704.32	1,704.32
Earnings Per Share						
Earnings Per Share (not annualised for quarter/ year / period ended)						
Basic / Diluted	0.29	0.32	(0.27)	0.76	0.02	0.18
Basic / Diluted (After Adjustment to Bonus Issue)	0.29	0.32	(0.27)	0.76	0.02	0.18



Notes to Accounts -Consolidated Financial Statement

- [1] The above Consolidated financial results for the quarter ended December 31, 2023 have been prepared by the Company in accordance with regulation 33 of SEI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on **06-02-2024**. A limited review of the above results has been carried out by the statutory auditors of the company.
- [2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified wherever considered necessary.
- [3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as amended] prescribed under section 133 of the companies act,2013.
- [4] The Management is in process of identifying parties which are covered under MSME, The Amount relating to MSME are disclosed to the extent identified.
- [5] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.
- [6] During the Quarter ended on 31.12.2023 Company has allotted 33,33,000 Equity shares as on 12.10.2023 at face value of Rs. 10.00 each at an issue Price Of Rs. 30.00 Per Equity Share(including Security Premium Of Rs. 20.00 per Equity Share). And the funds has been utilised as per the object.
- [7] During the Quarter ended on 31.12.2023 Company has issued 53,73,000 Convertible Warrants as on 12.10.2023 at a face value of Rs. 10.00 each, at an issue Price Of Rs. 30.00 per Warrants(including Security Premium Of Rs 20.00 per Equity Share), aggregating to Rs. 16,11,90,000 /- From Which 25% Amount Received on Issue Of Warrants. And the funds has been utilised as per the object.
- [8] The figure for the quarter ended 31.12.2023 are balancing figures between the unaudited figures in respect of half year ended on 30.09.2023 and the nine month ended figures upto the third quarter ended on 31.12.2023 which were subject to limited review.
- [9] The figure for the quarter ended 31.12.2022 are balancing figures between the unaudited figures in respect of half year ended on 30.09.2022 and the nine month ended figures upto the third quarter ended on 31.12.2022 which were subject to limited review.
- [10] The figure for the Nine Month ended on 31.12.2022 are balancing figures between the audited figures in respect of year ended on 31.03.2023 and the quarter ended figures on 31.03.2023.
- [11] The Status of investor's complaints during the period ended on December 31 ,2023 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

For, Deccan Health Care Limited


Minto P Gupta
(Managing Director)
(DIN: 00843784)



Date:- 06th February, 2024
Place: Hyderabad

Information about the Appointment of Mrs. Bhavika Sanghani

Sr. No.	Particulars	Details
1	Reason for Change Appointment, Reappointment Resignation, Removal, Death or Otherwise	Appointment as an Additional Director in the category of Independent Director. Based on the recommendation of the Nomination and Remuneration Committee of the Company, the Board of Directors has approved the appointment of Mrs. Bhavika Sanghani.
2	Date of appointment / reappointment cessation (as applicable) and term of appointment	With effective from 06.02.2024 for the period of 5 (Five) years i.e. From 06.02.2024 to 05.02.2027 The said appointment is subject to approval of shareholders and his appointment is not liable for retire by rotation.
3	Brief Profile (in case appointment)	Bhavika Sanghani, is Company Secretary by profession having 5 years of work experience and a Bachelor of Business Administration from DAVV University, Indore. She is currently working at Hindustan Waste Treatment Private Limited. Previously she was associated with companies like SMS-AABS India Tollways Private Limited and Parenteral Drugs (India) Limited and Parenteral Drugs (India) Limited (listed at BSE and NSE).
4	Disclosure of relationship between directors (in case appointment of a Director)	Nil
5	Shareholding in the company as on date of appointment	Nil
6	Names of listed entities in which the person also holds the directorship and the membership of Committees of the board	Mrs. Bhavika Sanghani does not hold a directorship in any listed entity.
7	Information pursuant to BSE Circular with ref. no. LIST/COMP/ 14/ 2018-19	Mrs. Bhavika Sanghani is not debarred from holding the office of a Director by virtue of any SEBI order or any other such authority as required under the circulars.

Registered office:

CIN: L72200TG1996PLC024351. Estd: 1996
Address : H.No. 6-3-348/4, Dwarkapuri
Colony, Punjagutta, Hyderabad,
Telangana-500082

Innovation Hub & manufacturing:

Address: Plot No.13, Sector-03, (SIDCUL), IIE,
Panthenagar, Udam Singh Nagar
-263153,U.K., India

Information about the Appointment of Mr. Umanja Venkata Satya Siva Srihari Kolla

Sr. No	Particulars	Details
1	Reason for Change Appointment, Reappointment Resignation, Removal, Death or Otherwise	Appointment
2	Date of appointment / reappointment cessation (as applicable) and term of appointment	Appointed Mr. Umanja Venkata Satya Siva Srihari Kolla as an Additional Non-Executive Director, with effect from 06th February, 2024 and recommended the said appointment to the shareholders. His appointment is not liable for retire by rotation.
3	Brief Profile (in case appointment)	Annexure A
4	Disclosure of relationship between directors (in case appointment of a Director)	Nil
5	Shareholding in the company as on date of appointment	Nil
6	Names of listed entities in which the person also holds the directorship and the membership of Committees of the board	Nil
7	Information pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018-19	Mr. Shri Hari is not debarred from holding the office of a Director by virtue of any SEBI order or any other such authority as required under the circulars.

Registered office:

CIN: L72200TG1996PLC024351. Estd: 1996
Address : H.No. 6-3-348/4, Dwarkapuri
Colony, Punjagutta, Hyderabad,
Telangana-500082

Innovation Hub & manufacturing:

Address: Plot No.13, Sector-03, (SIDCUL), IIE,
Panthnagar, Udam Singh Nagar
-263153,U.K., India

KUVSS SRIHARI

Strategic, performance-focused and result driven executive and serial entrepreneur with vast experience of innovative, energetic leadership. Expert in leveraging resources, capabilities, and relationships to gain advantage in grow business multifold. Inspirational leader known for clearly defining goals, aligning people and resources, and consistently delivering results that exceed expectations and always led by example.

Founder - Sreenidhi Group, India

Founded Sreenidhi - focuses on Infra, Realty, and Hospitality with the vision to create value for our customers. Based out of Hyderabad, this company is one of the pioneers in real estate of southern part of India. It has been a leader in the industry etching out benchmarking standards for the market to emulate. Since inception Sreenidhi has conceptualized, executed, and successfully completed projects ranging from condominiums, gated communities comprising of villas and apartments, Commercial and plotting layouts.

Director - Phoenix Group

Phoenix is a corporate conglomerate with business interests in Realty, Automobiles, Power, and Mining. At this role as a Director, He is primarily responsible for providing leadership and direction to the middle management across the India who execute critical day-to-day management of all over the projects. Manages budget, establish performance goals and objectives, and to measure outcomes ensuring operations run smoothly and deliver all project efficiently. Played pivotal role in the company growth and led to generation of record revenues in a shorter span of time to maintain healthy and positive P&L.

Founder - Aruntech Solutions Pvt Ltd, India

Founded tech startup which primarily focuses on outsourcing and staff augmentation services that significantly focuses on agility, efficiency, quality, and transparency. Its core functions included onsite and offshore augmentation of highly skilled IT professionals, consulting and Business analysis, Comprehensive Project Management, Domain knowledge and specialization in business know-how, international business consulting, executing large projects with global mobility.

Founder - SKB&SVR Memorial Trust

This foundation (SKB and SVR Charitable Trust in memory of his beloved parents) established and operate in Telangana and Andhra Pradesh. This Foundation has been providing financial assistance also promote social, cultural, educational, and humanitarian standards that help in alleviating the pain and suffering of the downtrodden and destitute people. This trust works with complete dedication and focus on reaching out to maximum needy segment of people with utmost compassion and empathy. The trust's endeavor is to spread its wings to shelter maximum helpless people and rekindle their belief in humanity and kindness.



+91-9122299999



srihari.k@phoenixindia.net



English, Telugu



Road No:45, Jubilee Hills,
Hyderabad, India, 500038

Details about the Appointment of Internal Auditor:

1	Name of Auditor	M/s. Malay Agarwal
2	Firm Registration No/Membership no.	437347
3	PAN Card	BPXPA9676P
4	Reason for change viz appointment, resignation, removal, death or otherwise;	Appointment in compliance with the provisions of the Companies Act, 2013
5	Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/ re-appointment	Internal Auditor has been appointed on 06.02.2024 for the F.Y. 2023-24
6	Brief profile (In case of Appointment)	Malay Agarwal is a Chartered Accountant, a Associate member of the Institute of Chartered Accountants of India and achelor of Commerce with almost 4 years of industry experience. He has experience in area of operational risk management with various corporates.
7	Disclosure of relationships between directors (in case of Appointment of a director)	Not Applicable

Registered office:

CIN: L72200TG1996PLC024351. Estd: 1996
Address : H.No. 6-3-348/4, Dwarkapuri
Colony, Punjagutta, Hyderabad,
Telangana-500082

Innovation Hub & manufacturing:

Address: Plot No.13, Sector-03, (SIDCUL), IIE,
Panthnagar, Udam Singh Nagar
-263153,U.K., India